MENA Metabolic Conference
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

AdobeStock 458919499

EVerZom signs research collaboration with GENFIT to advance exosome therapy

, 14 January 2026/in E-News /by panglobal

EVerZom, a French biotechnology company developing exosome-based therapies for regenerative medicine, has entered into a research collaboration with GENFIT, a biopharmaceutical company specialising in rare liver diseases. The partnership will evaluate EViv, EVerZom’s second proprietary investigational drug candidate, which has been developed to treat acute-on-chronic liver failure (ACLF).

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2026/01/AdobeStock_458919499.jpeg 1234 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2026-01-14 12:44:282026-01-14 12:45:30EVerZom signs research collaboration with GENFIT to advance exosome therapy
Scherm­afbeelding 2026 01 14 om 13.24.16

T-CURX secures $20M Series A for non-viral CAR-T therapy development

, 14 January 2026/in E-News /by panglobal

German biotech company T-CURX GmbH has announced the first closing of a $20M (€17.7M) Series A financing round to accelerate clinical development of its non-viral CAR-T cell therapies and advance proprietary in vivo CAR-T generation technologies. The funding round was led by BiomedVC, with participation from Bayern Kapital, HighLight Capital, i&iBio Fund, and existing and […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2026/01/Scherm­afbeelding-2026-01-14-om-13.24.16.jpg 550 1112 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2026-01-14 12:34:392026-01-14 12:34:39T-CURX secures $20M Series A for non-viral CAR-T therapy development
Scherm­afbeelding 2026 01 14 om 13.17.19

Sapio Sciences selected for Sanger Institute LIMS transformation

, 14 January 2026/in E-News /by panglobal

The Wellcome Sanger Institute has selected Sapio Sciences’ informatics platform as its central laboratory information management system (LIMS) to support a comprehensive digital transformation programme aimed at unifying genomics workflows across the organisation.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2026/01/Scherm­afbeelding-2026-01-14-om-13.17.19.jpg 704 1220 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2026-01-14 12:18:582026-01-14 12:19:38Sapio Sciences selected for Sanger Institute LIMS transformation
werfen logo

WERFEN APPLAUDS SIGNIFICANT PUBLICATION URGING ACTION ON THE RISKS OF UNDETECTED HEMOLYSIS

, 15 December 2025/in E-News /by panglobal

Clinical Experts Issue Special Report Calling for Greater Education, Testing, and Prevention of In Vitro Hemolysis in High-Risk Settings

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/08/werfen_logo.png 520 1647 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-15 08:53:082025-12-15 08:53:09WERFEN APPLAUDS SIGNIFICANT PUBLICATION URGING ACTION ON THE RISKS OF UNDETECTED HEMOLYSIS
indero gene expression analysis

Indero validates three-day gene expression method

, 13 December 2025/in E-News /by panglobal

Montreal-based contract research organisation Indero has completed an internally funded study demonstrating that quantitative gene expression analysis can assess topical new chemical entities in early-phase clinical research within three days, substantially reducing the time and cost associated with traditional evaluation methods.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/indero-gene-expression-analysis.jpg 1047 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-13 10:37:112025-12-11 10:51:45Indero validates three-day gene expression method
Johnson and Johnson Logo.svg

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion

, 12 December 2025/in E-News /by panglobal

Johnson & Johnson has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. for US$3.05 billion in cash, securing access to a clinical-stage prostate cancer therapy and a proprietary platform technology designed to develop oral targeted treatments for solid tumours. The transaction is expected to close within the coming months pending antitrust clearance […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/Johnson_and_Johnson_Logo.svg_.png 233 1280 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-12 10:32:542025-12-11 10:36:53Johnson & Johnson acquires Halda Therapeutics for $3.05 billion
alphasync

New AlphaSync database ensures protein structure predictions stay current

, 11 December 2025/in E-News /by panglobal

St. Jude Children’s Research Hospital scientists have launched AlphaSync, a free database addressing a critical gap in structural biology by continuously synchronising predicted protein structures with the latest sequence data from UniProt. The resource currently provides 2.6 million updated structural models across 925 species, including disease-relevant proteins previously missing from existing databases.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/alphasync.jpg 1258 1883 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-11 16:18:432025-12-11 16:18:43New AlphaSync database ensures protein structure predictions stay current
metabolomics research competition

NADMED launches $30,000 metabolomics competition

, 11 December 2025/in E-News /by panglobal

A Finnish biotechnology company has opened applications for a global scientific competition designed to advance understanding of cellular redox metabolism, offering successful applicants access to precision measurement technology and expert support valued at up to $30,000.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/NADMED.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-11 10:28:102025-12-11 10:32:33NADMED launches $30,000 metabolomics competition
Molcure AI drug discovery

Molcure partners with Boehringer Ingelheim to accelerate AI-driven antibody drug discovery

, 9 November 2025/in E-News /by panglobal

MOLCURE Inc. has announced a multiyear strategic research agreement with Boehringer Ingelheim to discover innovative antibody therapeutics for multiple targets using the Japanese company’s proprietary artificial intelligence platform technology. The collaboration will combine MOLCURE’s AI-driven platform with Boehringer Ingelheim’s expertise in biologics development, aiming to expand the scope and efficiency of antibody drug discovery beyond […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/Molcure-AI-drug-discovery.png 1707 1707 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-09 16:02:462025-11-06 16:08:36Molcure partners with Boehringer Ingelheim to accelerate AI-driven antibody drug discovery
StemInov stem cells

StemInov secures €10.6 million to advance mesenchymal stem cell therapy for severe pneumonia

, 8 November 2025/in E-News /by panglobal

French biopharmaceutical company StemInov has closed a €10.6 million financing round to support the industrialisation of its stem cell platform and prepare for Phase I/IIa clinical trials targeting severe pneumonia complications. The Nancy and Illkirch-Graffenstaden-based company, which specialises in mesenchymal stem cell (MSC) therapies for inflammatory and autoimmune diseases, expects to initiate patient recruitment in […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/StemInov_stem_cells.jpg 1184 864 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-08 16:25:292025-11-06 16:29:11StemInov secures €10.6 million to advance mesenchymal stem cell therapy for severe pneumonia
Page 4 of 231«‹23456›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

March 2026

CLi Cover MRCH 2026
11 March 2026

Isomorphic Labs unveils IsoDDE, a unified AI drug design engine surpassing AlphaFold 3 in biomolecular prediction

11 March 2026

Androgen testing for PCOS diagnosis

9 March 2026

DiaSys Diagnostic Systems | ACE FS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription